Our scientific focus centers on uracil-DNA metabolism, a previously underexplored but highly promising therapeutic pathway. By developing first-in-class small molecule drugs that selectively modulate this process, we aim to control abnormal cellular behaviour at its source. Our therapies are specifically designed to work in combination with widely used standard-of-care treatments — enhancing their effectiveness without adding toxicity.
Our lead oncology candidate, CV6-168, is currently progressing through a Phase 1a clinical trial (ISRCTN12434145). It is designed to alter the mechanism of action and greatly amplify the therapeutic impact of cornerstone therapies like 5-fluorouracil (5-FU), one of the most prescribed cancer drugs globally. In parallel, our preclinical inflammatory disease program targets rheumatoid arthritis and related conditions, with the goal of delivering disease-modifying treatment options for patients who currently have limited alternatives.
Backed by a growing pipeline, a robust intellectual property portfolio, and deep scientific expertise, CV6 Therapeutics is developing the next generation of combination-ready therapies to address large, established markets with significant unmet medical need.
